347 related articles for article (PubMed ID: 28483447)
1. Therapeutic targeting of the HIF oxygen-sensing pathway: Lessons learned from clinical studies.
Haase VH
Exp Cell Res; 2017 Jul; 356(2):160-165. PubMed ID: 28483447
[TBL] [Abstract][Full Text] [Related]
2. Hypoxia-induced erythropoietin production: a paradigm for oxygen-regulated gene expression.
Stockmann C; Fandrey J
Clin Exp Pharmacol Physiol; 2006 Oct; 33(10):968-79. PubMed ID: 17002676
[TBL] [Abstract][Full Text] [Related]
3. Oxygen sensors as therapeutic targets in kidney disease.
Haase VH
Nephrol Ther; 2017 Apr; 13 Suppl 1():S29-S34. PubMed ID: 28577740
[TBL] [Abstract][Full Text] [Related]
4. HIF stabilizers in the management of renal anemia: from bench to bedside to pediatrics.
Kular D; Macdougall IC
Pediatr Nephrol; 2019 Mar; 34(3):365-378. PubMed ID: 29569190
[TBL] [Abstract][Full Text] [Related]
5. Complement C1q is hydroxylated by collagen prolyl 4 hydroxylase and is sensitive to off-target inhibition by prolyl hydroxylase domain inhibitors that stabilize hypoxia-inducible factor.
Kiriakidis S; Hoer SS; Burrows N; Biddlecome G; Khan MN; Thinnes CC; Schofield CJ; Rogers N; Botto M; Paleolog E; Maxwell PH
Kidney Int; 2017 Oct; 92(4):900-908. PubMed ID: 28506759
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of hypoxia-inducible factor-prolyl hydroxylation protects from cyclophosphamide-induced bladder injury and urinary dysfunction.
Clayton DB; Tong CMC; Li B; Taylor AS; De S; Mason MD; Dudley AG; Davidoff O; Kobayashi H; Haase VH
Am J Physiol Renal Physiol; 2022 Jul; 323(1):F81-F91. PubMed ID: 35499237
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of prolyl hydroxylase domain-containing protein on hypertension/renal injury induced by high salt diet and nitric oxide withdrawal.
Dallatu MK; Choi M; Oyekan AO
J Hypertens; 2013 Oct; 31(10):2043-9. PubMed ID: 23811999
[TBL] [Abstract][Full Text] [Related]
8. HIF-prolyl hydroxylases as therapeutic targets in erythropoiesis and iron metabolism.
Haase VH
Hemodial Int; 2017 Jun; 21 Suppl 1(Suppl 1):S110-S124. PubMed ID: 28449418
[TBL] [Abstract][Full Text] [Related]
9. Novel roles of hypoxia response system in glucose metabolism and obesity.
Ichiki T; Sunagawa K
Trends Cardiovasc Med; 2014 Jul; 24(5):197-201. PubMed ID: 24774124
[TBL] [Abstract][Full Text] [Related]
10. Genetic Knockdown and Pharmacologic Inhibition of Hypoxia-Inducible Factor (HIF) Hydroxylases.
Pickel C; Taylor CT; Scholz CC
Methods Mol Biol; 2018; 1742():1-14. PubMed ID: 29330785
[TBL] [Abstract][Full Text] [Related]
11. Discovery and Preclinical Characterization of GSK1278863 (Daprodustat), a Small Molecule Hypoxia Inducible Factor-Prolyl Hydroxylase Inhibitor for Anemia.
Ariazi JL; Duffy KJ; Adams DF; Fitch DM; Luo L; Pappalardi M; Biju M; DiFilippo EH; Shaw T; Wiggall K; Erickson-Miller C
J Pharmacol Exp Ther; 2017 Dec; 363(3):336-347. PubMed ID: 28928122
[TBL] [Abstract][Full Text] [Related]
12. Hypoxia-Inducible Factor α and Hif-prolyl Hydroxylase Characterization and Gene Expression in Short-Time Air-Exposed Mytilus galloprovincialis.
Giannetto A; Maisano M; Cappello T; Oliva S; Parrino V; Natalotto A; De Marco G; Barberi C; Romeo O; Mauceri A; Fasulo S
Mar Biotechnol (NY); 2015 Dec; 17(6):768-81. PubMed ID: 26277612
[TBL] [Abstract][Full Text] [Related]
13. Notch Downregulation and Extramedullary Erythrocytosis in Hypoxia-Inducible Factor Prolyl 4-Hydroxylase 2-Deficient Mice.
Myllymäki MNM; Määttä J; Dimova EY; Izzi V; Väisänen T; Myllyharju J; Koivunen P; Serpi R
Mol Cell Biol; 2017 Jan; 37(2):. PubMed ID: 27821476
[TBL] [Abstract][Full Text] [Related]
14. The Endothelial Prolyl-4-Hydroxylase Domain 2/Hypoxia-Inducible Factor 2 Axis Regulates Pulmonary Artery Pressure in Mice.
Kapitsinou PP; Rajendran G; Astleford L; Michael M; Schonfeld MP; Fields T; Shay S; French JL; West J; Haase VH
Mol Cell Biol; 2016 May; 36(10):1584-94. PubMed ID: 26976644
[TBL] [Abstract][Full Text] [Related]
15. Lack of activity of recombinant HIF prolyl hydroxylases (PHDs) on reported non-HIF substrates.
Cockman ME; Lippl K; Tian YM; Pegg HB; Figg WD; Abboud MI; Heilig R; Fischer R; Myllyharju J; Schofield CJ; Ratcliffe PJ
Elife; 2019 Sep; 8():. PubMed ID: 31500697
[TBL] [Abstract][Full Text] [Related]
16. Prolyl hydroxylase mediated inhibition of fatty acid synthase to combat tumor growth in mammary gland carcinoma.
Singh M; Devi U; Roy S; Gupta PS; Saraf SA; Kaithwas G
Breast Cancer; 2016 Nov; 23(6):820-829. PubMed ID: 26951539
[TBL] [Abstract][Full Text] [Related]
17. Hypoxia-Inducible Factor and Its Role in the Management of Anemia in Chronic Kidney Disease.
Kaplan JM; Sharma N; Dikdan S
Int J Mol Sci; 2018 Jan; 19(2):. PubMed ID: 29382128
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of hypoxia-inducible factor prolyl hydroxylase domain oxygen sensors: tricking the body into mounting orchestrated survival and repair responses.
Rabinowitz MH
J Med Chem; 2013 Dec; 56(23):9369-402. PubMed ID: 23977883
[TBL] [Abstract][Full Text] [Related]
19. Effects of prolyl-hydroxylase inhibition and chronic intermittent hypoxia on synaptic transmission and plasticity in the rat CA1 and dentate gyrus.
Wall AM; Corcoran AE; O'Halloran KD; O'Connor JJ
Neurobiol Dis; 2014 Feb; 62():8-17. PubMed ID: 24055213
[TBL] [Abstract][Full Text] [Related]
20. Investigational hypoxia-inducible factor prolyl hydroxylase inhibitors (HIF-PHI) for the treatment of anemia associated with chronic kidney disease.
Del Vecchio L; Locatelli F
Expert Opin Investig Drugs; 2018 Jul; 27(7):613-621. PubMed ID: 29975110
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
